Stockwinners Market Radar for April 19, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Windtree Therapeutics Inc trading halted, news pending

18:01 EDT NovaBay receives NYSE American notice of non-compliance - NovaBay Pharmaceuticals announces that on April 18, it received a notice from the NYSE American stating that the company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity. The company must submit a plan by May 18 advising of actions it has taken or will take to regain compliance with the continued listing standards by October 18, 2025 in order to continue its listing on the NYSE American. The company intends to submit a plan to regain compliance to the NYSE American within the prescribed timeframe.

17:30 EDT Wrap Technologies receives noncompliance notification from Nasdaq - Wrap Technologies reported that it has received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the company that it is not in compliance with the requirements of Nasdaq Listing Rule 5250 as a result of not having timely filed its annual report on Form 10-K for the fiscal year ended December 31, 2023, with the SEC.

17:19 EDT Arista Networks COO Anshul Sadana to resign, effective May 21 - In a regulatory filing, Arista Networks disclosed that on April 18, Anshul Sadana, the company's COO, notified the company of his intention to resign, effective May 21. Sadana's decision was not the result of any disagreement with the company.

17:08 EDT Hepion Pharmaceuticals falls 42% after wind down of ASCEND-NASH trial - In after-hours trading, shares are down 42% to $1.20

17:05 EDT NLS Pharmaceutics receives staff delisting determination letter from Nasdaq - NLS Pharmaceutics announces that on April 17, it received a determination letter from the staff of the Listing Qualifications Department of The Nasdaq Stock Market notifying the company of the Staff's determination that, unless the company timely requests a hearing before a Nasdaq Hearings Panel, the company's securities would be subject to delisting from The Nasdaq Capital Market due to the company's failure to maintain at least a $1 bid price per share over the course of 30 consecutive business days, as set forth in Nasdaq Listing Rule 5550(a)(2). Accordingly, the company intends to timely request a hearing before the Panel. The hearing request will stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. At the hearing, the company intends to present a plan to achieve compliance with the bid price requirement, as well as any other applicable Nasdaq listing requirements, and to request that the Panel allow the company additional time to regain such compliance. However, there can be no assurance that the Panel will grant the company's request for an extension or that the company will ultimately regain compliance with all applicable requirements for continued listing.

17:00 EDT Hepion Pharmaceuticals trading resumes

16:33 EDT Odyssey Marine addresses Nasdaq compliance matters - Odyssey Marine Exploration reported that on April 17, 2024, Odyssey received a notice from Nasdaq Regulation that Odyssey is not in compliance with Nasdaq Rule 5250(c)(1) because it had not yet filed its Form 10-K for the period ended December 31, 2023 with the Securities and Exchange Commission. Odyssey plans to regain compliance with Nasdaq Rule 5250(c)(1) by filing the Form 10-K with the SEC, which it expects to do as soon as practicable.

16:29 EDT Vaxxinity to voluntarily delist, deregister its Class A common stock - Vaxxinity announced its intention to voluntarily delist from the Nasdaq Global Market and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended, and suspend its reporting obligations under Section 15(d) of the Exchange Act. On April 19, the company notified Nasdaq of its intent to voluntarily delist its Class A common stock from Nasdaq. The company currently anticipates that it will file with the SEC a Form 25 relating to the delisting and deregistration of its Class A common stock on or about April 29, 2024, and anticipates that the delisting and deregistration under Section 12(b) of its Class A common stock will then become effective on or about May 9, 2024. Following the delisting, any trading in the company's Class A common stock would only occur in privately negotiated sales and potentially on an over-the-counter market. The company expects that its Class A common stock will initially be quoted on a market operated by OTC Markets Group so that a trading market may continue to exist for its Class A common stock for some period of time. There is no guarantee, however, that a broker will continue to make a market in the Class A common stock and that trading of the Class A common stock will continue on an OTC market or otherwise.

16:18 EDT Crown Castle to not include Steven Moskowitz on slate of director nominees - Crown Castle issued the following statement: "Consistent with the Boots Group's approach throughout its campaign, Ted Miller has again pursued a litigation strategy that is attempting to interfere with Crown Castle's critical strategic and operational initiatives. In his most recent motion, Ted Miller is seeking to prevent the Company from expanding the size of its Board, which the Board has recently done by adding Steven Moskowitz as a director at the time of Mr. Moskowitz's appointment as Crown Castle's President and CEO. Although the Company vigorously disputes the claims in the Boots Group's lawsuit, Crown Castle has decided it will not include Steven Moskowitz on its slate of director nominees for the Company's 2024 Annual Meeting of Stockholders to avoid the distraction and expense of Ted Miller's litigation. Shareholders will continue to have the opportunity to vote on the Company's remaining 12 highly qualified incumbent directors. All the current independent directors of the Board intend to vote to appoint Mr. Moskowitz to the Board immediately after the 2024 Annual Meeting. The Company and CEO Steven Moskowitz will continue to focus on advancing initiatives aimed at creating value for all shareholders."

16:06 EDT Warrantee receives Nasdaq delisting determination - Warrantee announced that the Company received a staff determination letter, on April 15, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, due to the Company's failure to regain compliance with a minimum bid price of $1.00 per share requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2), the Staff has determined that Company's securities will be scheduled for delisting from Nasdaq unless the Company requests an appeal of this determination to a Hearings Panel. On October 13, 2023, the Company received a letter from Nasdaq, notifying the Company that based upon the closing bid price of its securities for the last 30 consecutive business days preceding the Notice, the Company was not in compliance with the Minimum Bid Requirement. In accordance with Listing Rule 5810(c)(3)(A), the Notice provided the Company a period of 180 calendar days from the date of the Notice, or until April 10, 2024, to regain compliance with the Minimum Bid Requirement. According to the Letter, the Company had not regained compliance with the Minimum Bid Requirement as of April 10, 2024 and is not eligible for a second 180-day period. Specifically, the Company does not comply with the initial listing requirement of $5,000,000 minimum stockholders' equity for The Nasdaq Capital Market, as contemplated for a second 180-day period. Further, on April 4, 2024, Nasdaq notified the Company that since the Company failed to file its Form 6-K containing an interim balance sheet and income statement for the six-month period ended September 30, 2023, it no longer complies with our Listing Rule 5250(c)(2). This matter serves as an additional and separate basis for delisting. Unless the Company requests an appeal of the Determination by April 22, 2024, the Company's securities will be suspended at the opening of business on April 24, 2024, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company's securities from listing and registration on Nasdaq.

14:02 EDT Arcline completes acquisition of Kaman - Kaman announced the completion of its acquisition by Arcline Investment Management in an all-cash transaction with a total enterprise value of approximately $1.8B. The transaction was previously announced on January 19 and was approved by Kaman shareholders on April 17. With the completion of the transaction, Kaman shareholders will receive $46.00 per share in cash. Kaman's common stock has ceased trading and will be delisted from the New York Stock Exchange.

13:02 EDT Baker Hughes reports U.S. rig count up 2 to 619 rigs - Baker Hughes reports that the U.S. rig count is up 2 from last week to 619 with oil rigs up 5 to 511, gas rigs down 3 to 106 and miscellaneous rigs unchanged at 2. The U.S. Rig Count is down 134 rigs from last year's count of 753 with oil rigs down 80, gas rigs down 53 and miscellaneous down 1. The U.S. Offshore Rig Count is up 1 to 20, unchanged year-over-year. The Canada Rig Count is down 14 from last week to 127, with oil rigs down 10 to 60, and gas rigs down 4 to 67. The Canada Rig Count is up 22 from last year's count of 105, with oil rigs up 18, and gas rigs up 4.

12:59 EDT Amazon Music says Taylor Swift's new album most-streamed in first day ever - Taylor Swift's 11th studio album, "THE TORTURED POETS DEPARTMENT," just became the most-streamed album in its first day ever on Amazon Music, the service announced. Reference Link

12:47 EDT Four Seasons Edu (Cayman) Inc ADR trading halted, volatility trading pause

12:31 EDT Bentley Systems acknowledged Schneider statement over talks - Bentley Systems (BSY) acknowledged earlier today the public statement made by Schneider Electric (SBGSY) in response to recent market speculation. "Bentley does not publicly comment on market rumors or speculation and does not intend to comment on this matter," the company said. Schneider Electric confirmed that it has been holding discussions with Bentley with regards to a potential strategic transaction. "Discussions remain at a preliminary stage regarding a potential transaction, and there is no certainty that any transaction will be agreed upon. No further comment will be made until an update is warranted," it added. Shares of Bentley are down 28c to $51.78 in midday trading. Reuters reported yesterday that Bentley is exploring options that include a sale after attracting acquisition interest.

12:27 EDT Mondi board decides DS Smith offer 'not in best interests' of shareholders - Mondi (MONDY) notes the terms of the recommended all-share combination of International Paper Company (IP) with DS Smith Plc (DITHF)) announced on April 16. Mondi said: "Following a period of due diligence, and after carefully considering the value the combination with DS Smith would deliver to Mondi's shareholders, the Mondi Board has decided that the transaction would not be in the best interests of its shareholders. Accordingly, Mondi does not intend to make an offer for DS Smith. Mondi's Board remains confident that its compelling portfolio of sustainable packaging and paper products, scale and cost advantaged quality asset base, along with its pipeline of organic investments, ensure it is well positioned to deliver long-term structural growth in the markets in which it operates, delivering strong cash generation, attractive returns and sustainable value accretive growth for shareholders." Reference Link

12:15 EDT Pieris Pharmaceuticals announces 1-for-80 reverse stock split - Pieris Pharmaceuticals announced that its Board of Directors has approved a 1-for-80 reverse stock split of the company's common stock, par value 0.1c, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on April 23, 2024, under the company's existing trading symbol "PIRS". The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the company's common stock for continued listing on The Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 720795202. The company filed a Certificate of Change with the Nevada Secretary of State on April 18, 2024 to effect the reverse split.

12:00 EDT AMC Entertainment rises 9.1% - AMC Entertainment is up 9.1%, or 27c to $3.19.

12:00 EDT Metropolitan Bank rises 18.8% - Metropolitan Bank is up 18.8%, or $6.22 to $39.32.

12:00 EDT Celestica falls -5.9% - Celestica is down -5.9%, or -$2.60 to $41.21.

11:56 EDT Adlai Nortye Ltd (ADR) trading halted, volatility trading pause

10:00 EDT Cohen & Steers rises 7.5% - Cohen & Steers is up 7.5%, or $4.94 to $71.05.

10:00 EDT CoreCard falls -4.2% - CoreCard is down -4.2%, or -49c to $11.19.

10:00 EDT NL Industries falls -6.0% - NL Industries is down -6.0%, or -46c to $7.18.

09:47 EDT BWX Technologies to invest C$80M in expansion of Cambridge plant - BWX Technologies announced an investment to expand its Cambridge manufacturing plant. Already one of the largest nuclear commercial manufacturing facilities in North America, the site's increased footprint will enable greater capacity to support ongoing and anticipated customers' investments in Small Modular Reactors, traditional large-scale nuclear and advanced reactors, in Canada and around the world. The expansion, estimated to cost C$50M, will increase the facility's footprint 25 percent to 280,000 square feet. Additionally, over the next few years, BWXT will invest approximately C$30M in advanced manufacturing equipment for the facility that has designed and manufactured hundreds of large nuclear components. This total estimated C$80M investment will increase capacity significantly, improve productivity and create more than 200 long-term jobs for skilled workers, engineers and support staff in the area. Construction for the BWXT Cambridge Expansion Project is expected to begin in the third quarter of 2024, adjacent to the existing plant, with no interruption to ongoing operations at the current facility. The project is estimated to be completed by the middle of 2026. Additionally, BWXT's Projects and Field Services business will relocate to a stand-alone 150,000 square foot facility in Kitchener, Ont. The facility in Kitchener will be a state-of -the-art center for training, dynamic learning and technology development supporting the growth of the company's nuclear business.

09:47 EDT CoreCard falls -4.8% - CoreCard is down -4.8%, or -56c to $11.12.

09:47 EDT Lifezone Metals rises 4.4% - Lifezone Metals is up 4.4%, or 34c to $8.14.

09:47 EDT Cohen & Steers rises 11.8% - Cohen & Steers is up 11.8%, or $7.80 to $73.91.

09:23 EDT Progress Software considering possible 60c per share offer for MariaDB - Further to the announcement made by Progress Software (PRGS) on March 26, 2024, Progress is announcing, under Rule 2.4 of the Irish Takeover Rules, that it is considering a possible offer to acquire all of the debt and the entire issued and to be issued share capital of MariaDB (MRDB). Under the Possible Offer, each MariaDB shareholder would be entitled to receive $0.60 for each MariaDB share, payable in cash. The Possible Offer would represent a premium of approximately: 9 per cent. to the possible offer of $0.55 per share made by K1 Capital, announced on February 16, 2024; 88 per cent. to MariaDB's average closing share price on the last 30 trading days prior to the March Possible Offer Announcement; and 216 per cent. to MariaDB's closing share price on February 5, 2024, the last full trading day prior to the announcement by MariaDB of a forbearance agreement with RP Ventures LLC. The Possible Offer values MariaDB's entire issued ordinary share capital at approximately $40.6 million. In addition, in connection with the closing of the transactions contemplated by the Possible Offer, Progress proposes that it would complete the purchase or repayment of the Senior Secured Promissory Note issued by MariaDB to RP Ventures, a company associated with Runa Capital, on October 10, 2023, with RP Ventures being entitled to receive: $40 million in total with respect to the RP Note. This represents a premium of approximately 55 per cent. to the outstanding amount of the RP Note including the principal and accrued interest as of March 31, 2024 of approximately $25.9 million. The Possible Offer implies an enterprise value of approximately $100.6 million and a multiple of approximately 2 times MariaDB's revenue for the twelve months ended December 31, 2023. Given the liquidity challenges faced by MariaDB, there are other potential outstanding liabilities, estimated to be approximately $20 million, which would be assumed by Progress should it complete an acquisition of MariaDB. Progress is engaging with stakeholders with a view towards making a firm offer, under Rule 2.7 of the Irish Takeover Rules, to acquire all of the debt and the entire issued and to be issued share capital of MariaDB as quickly as possible.

09:09 EDT Procter & Gamble says consumption trends 'strong, with few exceptions' - Says soft market consumption in China, some impact from tensions in Middle East. Says headwinds "temporary in nature." Says "fully focused" on accelerating growth in China. Says organic sales in China improving quarter over quarter. Feels "very good about where we are" regarding productivity pipeline. Says "great visibility" on pipeline over next three years. Expects U.S. volume to grow in coming quarters. Says continues to invest in marketing.

08:59 EDT M.D.C. Holdings to be delisted from the NYSE due to acquisition by Sekisui House - M.D.C. Holdings is to be delisted from the NYSE due to its acquisition by Sekisui House for $63.00 per share in cash, representing a transaction equity value of $4.9B. The acquisition was completed on April 19.

08:58 EDT Trump Media tells Nasdaq CEO of 'potential market manipulation' - On April 18, 2024, Trump Media Technology Group sent a letter to Nasdaq regarding suspected short selling activity in the shares of the company. The letter from Devin Nunes, CEO of Trump Media, to Nasdaq CEO Adena Friedman states in part: "I write to bring your attention to potential market manipulation of the stock of Trump Media & Technology Group Corp., which operates the Truth Social platform and has traded on the Nasdaq Stock Market under the ticker 'DJT' since March 26, 2024. As you know, 'naked' short selling-selling shares of a stock without first borrowing the shares of stock deemed difficult to locate-is generally illegal pursuant to Securities and Exchange Commission Regulation SHO. As of April 17, 2024, DJT appears on Nasdaq's 'Reg SHO threshold list,' which is indicative of unlawful trading activity. This is particularly troubling given that 'naked' short selling often entails sophisticated market participants profiting at the expense of retail investors...In light of the foregoing, and Nasdaq's obligation and commitment to protect the interests of retail investors, please advise what steps you can take to foster transparency and compliance by ensuring market makers are adhering to Reg SHO, requiring brokers to disclose their 'Net Short' positions, and preventing the lending of shares that do not exist."

08:58 EDT M.D.C. Holdings acquired by Sekisui House for $4.9B - M.D.C. Holdings announced that Sekisui House, through SH Residential Holdings, a subsidiary of Sekisui House US Holdings, its U.S. business controlling company, has completed its acquisition of M.D.C. Holdings. With this addition, Sekisui House expects to achieve its goal of supplying 10,000 detached homes in overseas markets by fiscal year 2025, ahead of schedule. Sekisui House acquired MDC for $63.00 per share in cash, representing a transaction equity value of $4.9B. MDC will be delisted from the NYSE.

08:49 EDT Tritium DCFC trading halted, news pending

08:43 EDT American Resources' ReElement expands rights for REE purification tech - American Resources Corporation's ReElement Technologies Corporation announced that Purdue University has expanded ReElement's exclusive use of the patents for licensed ligand assisted displacement chromatography and knowhow for all feedstocks to now include rare earth ores. These exclusive patents and technologies, developed at Purdue University, have been utilized by ReElement at its Noblesville, Indiana Commercial Qualification Facility to produce ultra-pure rare earth oxides and critical battery elements to the growing magnet and energy storage industries. ReElement has successfully developed its critical mineral platform technology providing a high performance and scalable solution for separating, purifying and refining rare earth and critical elements in an efficient, low cost and environmentally safe process outside of China. ReElement is currently evaluating or in conversations with providers of rare earth ores from four different continents with the goal of either partnering with such parties or acquiring their rare earth concentrates to be refined domestically. Rare earth elements include the 15 elements in the lanthanide series plus scandium and yttrium. They are essential ingredients for high-end commercial and national defense applications in magnets, metal alloys, catalysts, ceramics, and phosphors, which are important for high-technology and clean energy applications

08:37 EDT AGBA Group says Triller merger 'elevating shareholder value to new heights' - AGBA Group has previously announced that on April 16, 2024, it had entered into a definitive merger agreement to combine AGBA with Triller. Upon completion of the Transaction, AGBA will become a Delaware corporation that wholly owns Triller, and AGBA itself will be majority-owned by current Triller stockholders and restricted stock unit holders. The Boards of Directors of Triller and AGBA have agreed to value the Combined Group at $4.0 billion. Triller shareholders will own 80% of the pro forma Combined Group representing a valuation of US$3,200 million. AGBA has 74.4 million shares outstanding, and current AGBA shareholders will own 20% of the pro forma Combined Group; the implied value of AGBA's current outstanding shares at $800 million is $10.75 per share. The Merger Agreement provides that, prior to the effective date of the Merger, AGBA will domesticate to the United States as a Delaware corporation and will, for all purposes of the laws of the State of Delaware, be deemed to be the same entity as AGBA. Upon the Domestication, among other things, all AGBA ordinary shares, par value $0.001 per share will automatically convert into the same number of shares of common stock of Delaware Parent.

08:34 EDT Collective Audience appoints Stacey Hawes to Advisor Collective - Collective Audience appointed Stacey Hawes to the Advisor Collective, the strategic advisory board the company formed earlier this year to support the transformation and advancement of the AdTech, MarTech and digital media industries. Hawes is currently the chief and data officer of MERGE, a full-service agency serving clients in retail, health, life sciences, and financial services.

08:32 EDT Lifeward appoints Swinford to board of directors - ReWalk Robotics announced that the Board has approved the appointment of Mike Swinford to the Board of Directors, effective April 18, 2024. Swinford has been Chief Executive Officer of Numotion since July 2014.

08:31 EDT La Rosa Holdings regains compliance with Nasdaq - La Rosa Holdings announced that on April 18, 2024, it received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market, informing the Company that it has regained compliance with Nasdaq Continue Listing Rules by satisfying Nasdaq's Equity Standard under Listing Rule 5550(b). Joe La Rosa, CEO of the Company, commented, "We are pleased to announce that the Company has regained compliance with Nasdaq's continued listing requirements. We believe that this accomplishment underscores our unwavering commitment to corporate governance and generating lasting value for shareholders. In our view, La Rosa stands out in the real estate industry with our distinctive brokerage model, offering agents the choice between a revenue share model or an annual fee-based model with 100% agent commissions. We remain focused on executing our roll-up strategy, acquiring profitable franchisees, solidifying our market position, and delivering sustainable growth for shareholders."

08:17 EDT Huntington Bancshares sees FY24 net interest income down 2% to up 2% - Sees FY24 average loans up 3%-5%. Sees FY24 average deposits up 2%-4%. Sees FY24 noninterest income up 5%-7%. Sees FY24 noninterest expense up 4.5%. Sees FY24 net charge-offs 25-35 basis points. Sees FY24 effective tax rate 19%. Says believes there will eventually be rate cuts. Sees Q1 as trough for net interest income. Comments and guidance taken from Q1 earnings conference call.

08:12 EDT Fifth Third reports Q1 net interest margin 2.86% vs 3.29% last year - Average deposits increased 5% compared to 1Q23.

08:10 EDT Biodexa Pharmaceuticals directors continue to adopt going concern basis - The company said, "The Group and Company has experienced net losses and significant cash outflows from cash used in operating activities over the past years as it develops its portfolio. For the year ended 31 December 2023, the Group incurred a consolidated loss for the year of GBP 7.08m and negative cash flows from operations of GBP 6.83m. As of 31 December, 2023, the Group had an accumulated deficit of GBP 142.82 m. The Group's future viability is dependent on its ability to raise cash from financing activities to finance its development plans until milestones and/or royalties can be secured from partnering the Company's assets. The Group's failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. The Directors believe there are adequate options and time available to secure additional financing for the Company and after considering the uncertainties, the Directors consider it is appropriate to continue to adopt the going concern basis in preparing these financial statements. The Group's consolidated financial statements have therefore been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As at 31 December 2023, the Group had cash and cash equivalents of GBP 5.97m. The Directors have prepared cash flow forecasts and considered the cash flow requirement for the Group for the next three years including the period 12 months from the date of approval of the consolidated financial statements. These forecasts show that further financing will be required before the fourth quarter of 2024 assuming, inter alia, that certain development programs and other operating activities continue as currently planned. If the Company does not secure additional funding before the fourth quarter of 2024, it will no longer be a going concern and would likely be placed in Administration. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the timing of clinical trials. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. If we lack sufficient capital to expand our operations or otherwise capitalize on our business opportunities, our business, financial condition and results of operations could be materially adversely affected. If we raise additional funds through the issuance of debt securities or additional equity securities, it could result in dilution to our existing shareholders, increased fixed payment obligations and these securities may have rights senior to those of our ordinary shares (including the ADSs) and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial condition and prospects. In the Directors' opinion, the environment for financing of small and micro-cap biotech companies remains challenging. While this may present acquisition and/or merger opportunities with other companies with limited or no access to financing, as noted above, any attendant financings by Biodexa are likely to be dilutive. The Directors continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially available to the Group. Any alternatives considered are contingent upon the agreement of counterparties and accordingly, there can be no assurance that any alternative courses of action to finance the Company would be successful. This requirement for additional financing in the short term represents a material uncertainty that may cast significant doubt upon the Group and Parent Company's ability to continue as a going concern. Should it become evident in the future that there are no realistic financing options available to the Company which are actionable before its cash resources run out then the Company will no longer be a going concern. In such circumstances, we would no longer be able to prepare financial statements under paragraph 25 of IAS 1. Instead, the financial statements would be prepared on a liquidation basis and assets would be stated at net realizable value and all liabilities would be accelerated to current liabilities."

08:04 EDT ContextLogic announces stockholder approval of transaction with Qoo10 - ContextLogic announced its stockholders have approved the Asset Sale transaction with Qoo10 at yesterday's Special Meeting of Stockholders. The transaction is expected to close later today, April 19, 2024. Rishi Bajaj, who will become Chief Executive Officer and Chairman of the Board at the closing of the Asset Sale, stated: "On behalf of the Board of Directors, we would like to thank our stockholders for their support of the Asset Sale. Having achieved this important milestone, we look forward to closing the transaction later today and using the proceeds and our other post-closing cash to maximize the value of the Company's NOLs for the benefit of our stockholders."

08:03 EDT Vail Resorts reports ski season-to-date visits down 7.8% y-o-y - Vail Resorts reported certain ski season metrics for the comparative periods from the beginning of the ski season through April 14, 2024, and for the prior year period through April 16, 2023. The reported ski season metrics are for the company's North American destination mountain resorts and regional ski areas, excluding the results of the Australian ski areas and Andermatt-Sedrun in both periods. Season-to-date total skier visits were down 7.8% compared to the prior year season-to-date period. Season-to-date total lift ticket revenue was up 3.2% compared to the prior year season-to-date period. Season-to-date ski school revenue was up 7.0% and dining revenue was up 2.4% compared to the prior year season-to-date period. Retail/rental revenue for North American resort and ski area store locations was down 7.1% compared to the prior year season-to-date period. CEO Kirsten Lynch said, "Given the unfavorable conditions across our North American resorts for a large portion of the season, we are pleased with our overall results as the 2023/2024 North American ski season nears completion...While visitation declined, our lift revenue increased driven by the growth in pass sales committed ahead of the season, and our ancillary businesses performed well, with particularly strong growth in spending per visit in our ski and ride school, dining, and rental businesses compared to the same period in the prior year. While late season results improved, we now expect to finish the year at or around the low end of our Resort Reported EBITDA guidance range issued on March 11, 2024, primarily driven by Whistler Blackcomb performance in the March and April period...Turning to the 2024/2025 season, to date, through the April deadline, we have seen a modest decline in pass product units and growth in sales dollars..."

08:01 EDT Steakholder Foods regains Nasdaq compliance - Steakholder Foods announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market informing the company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

07:58 EDT Tesla recalling 3,878 Cybertrucks over faulty accelerator pedal - Tesla is recalling 3,878 2024 Cybertruck vehicles as the accelerator pedal pad may dislodge and become trapped by the interior trim, th National Highway Traffic Safety Administration posted on its website. Tesla service will replace or repair the accelerator pedal assembly, free of charge, the agency noted.

07:47 EDT Jacobs selected for seawater desalination plant in Australia - Jacobs was selected by Water Corporation, the largest water utility in Western Australia, to design, build, operate and maintain the Alkimos Seawater Desalination Plant in Perth, Australia. The project, part of an alliance with Water Corporation and ACCIONA, is expected to produce 13 billion gallons of drinking water per year, scalable up to 26 billion gallons under a future project. Part of an overall program by Water Corporation estimated at approximately $1.83B, the plant will secure a climate-independent, sustainable water supply to more than 2.5 million Western Australians.

07:31 EDT Huize partners with PICC Life Insurance to launch 'i Wu You' insurance product - Huize Holding announced that it has partnered with PICC Life Insurance Company Limited to launch "i Wu You - Low-Threshold Edition", the latest customized critical illness insurance product in the "i Wu You" series that offers a personalized solution with a relaxed health declaration process to customers. Cunjun Ma, Chairman and Chief Executive Officer of Huize, commented, "Through our partnership with PICC Life, we launched this product to offer protection and reassurance to a wider range of customers with sub-health. We streamlined the underwriting process to take into account variations in individual health and insurance needs. This not only allows our insurance carrier partners to broaden their customer base but also extends protection to customers with pre-existing conditions."

07:10 EDT Amcon Distributing acquires Richmond Master Distributors, terms undisclosed - Amcon Distributing announced it has signed an asset purchase agreement to acquire Richmond Master Distributors of South Bend, Indiana. Amcon will continue to serve Master Distributors customers from its location in South Bend. Upon completion of this acquisition, Amcon will be servicing approximately 7,900 locations in 33 states. The transaction is expected to close in the company's third quarter of fiscal 2024, subject to customary closing conditions.

07:02 EDT ProQR Therapeutics defends against challenge to Axiomer IP portfolio - ProQR Therapeutics announced it has defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer. The opposition was filed in June 2021 with the European Patent Office by a strawman against ProQR's granted patent EP 3 507 366 B1, which relates to editing oligonucleotides that have certain chemical modifications in the base and/or ribose sugar to increase stability and recruit endogenous ADAR to edit the target adenosine. This patent is part of ProQR's intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules. The Opposition Division of the EPO held a public hearing on April 17, 2024, and ruled such that ProQR's strong IP position on chemically modified editing oligonucleotides was maintained. The patent contains broad platform claims including: "An antisense oligonucleotide (AON) capable of forming a double stranded complex with a target RNA sequence in a cell, preferably a human cell, for the deamination of a target adenosine in the target RNA sequence by an ADAR enzyme present in the cell...", which protects ProQR's proprietary ADAR mediated RNA editing platform Axiomer. "This decision further supports the confidence we have in the broad scope conferred by our IP estate protecting our proprietary Axiomer ADAR-mediated RNA editing technology platform, and the use of chemically modified oligonucleotides to increase stability and recruit endogenous ADAR to edit the target adenosine," said Rene Beukema, Chief Corporate Development Officer and General Counsel. "Given the importance and value of our IP portfolio, we intend to continue to defend against such challenges and remain confident in our leading position, as we progress our science, platform, and pipeline."

06:52 EDT SLB targeting to return $7B to shareholders over 2024-2025 - "Based on our strong start to the year, confidence in our ability to generate robust cash flows, and the anticipated contribution of the announced ChampionX acquisition, we are targeting to return $7 billion to shareholders over the next two years. This represents a target for returns to shareholders of $3 billion in 2024 and $4 billion in 2025."

06:14 EDT Alvotech signs agreement with Teva to bring Adalimumab-ryvk to U.S. market - Alvotech (ALVO) announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly FDA approved high-concentration interchangeable biosimilar to Humira. The current multi-product commercialization partnership between Teva Pharmaceuticals (TEVA) and Alvotech remains unchanged and Teva will continue to commercialize adalimumab-ryvk under the Simland brand in the U.S.

06:06 EDT Emeren receives noncompliance notification from NYSE - Emeren announced that it received a notice from the New York Stock Exchange, or NYSE, indicating non-compliance with the NYSE's continued listing requirements due to the delayed filing of its annual report on Form 10-K for the fiscal year ended December 31, 2023. This notification, while highlighting the need for timely filings under Section 802.01E of the NYSE Listed Company Manual, does not immediately affect the listing of Emeren's common stock. The NYSE has provided Emeren a six-month period, until October 16, to file the Form 10-K and regain compliance. There is a possibility for an extension of up to six additional months, depending on the company's progress and specific circumstances. The NYSE may also initiate delisting procedures if deemed necessary.

05:14 EDT Himax announces collaboration with E Ink - Himax announced a collaboration with E Ink to introduce an ultralow power battery-operated smart retail solution at the upcoming 2024 Touch Taiwan. The solution incorporates Himax's WiseEye ultralow power AI sensing technology with E Ink's signage EPD, featuring E Ink's Kaleido display, and ESL. Leveraging WiseEye, the smart retail solution deploys context-aware AI in human presence and shopper insight detection while also enhancing the battery life of an ePaper display and enabling real-time personalized marketing.